SGLT-2抑制剂治疗糖尿病肾病的研究进展(4)
[13] Sahasrabudhe V，Terra SG，Hickman A，et al. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus [J]. J Clin Pharmacol，2017，57(11)：1432-1443.[14] Seino Y，Yabe D，Sasaki T，et al. SGLT2 inhibitor luseog-liflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes：a 52-week ......
您现在查看是摘要页，全文长 2549 字符。